Veracyte's 17%-18% Growth Target Hinges on Prosigna and TrueMRD

Veracyte's core business is still funding the expansion

Veracyte's story is getting broader, not less grounded. Two new tests are extending the company further along the cancer-care continuum, while the core business remains strong enough to help finance the rollout. In the latest quarter, Veracyte posted total revenue of $150.3 million and testing revenue of $145.7 million, up 19% year over year. Management is also targeting 17%-18% full-year testing growth for 2026, even as it excludes new-launch contribution from that outlook. That leaves room for upside if Prosigna and TrueMRD begin to contribute meaningfully.

The launch strategy also matters. Earlier this year, Veracyte launched Prosigna as an LDT and TrueMRD for MIBC, adding tests tied to new clinical decision points rather than relying only on repeat demand from legacy products. That broadens the opportunity, but it also raises the execution bar. For now, the core business still looks like the funding base for the expansion rather than a mature line being asked to simply support a narrative.

Prosigna has the clearest near-term decision-point appeal

Of the two launches, Prosigna looks like the more immediate commercial engine because it can help shape a high-stakes treatment choice. Starting June 8, 2026, the test became available to order in the U.S. after the OPTIMA trial attracted attention at ASCO. That timing helps connect the assay to an active clinical decision rather than leaving it as background information.

Why clinicians may find a use for it

Prosigna is intended for early-stage, hormone-receptor positive breast cancer, and it determines a patient's Risk of Recurrence score while helping predict whether higher-risk patients are likely to benefit from chemotherapy. In OPTIMA, 68% of these patients may safely avoid chemotherapy when Prosigna guided the decision. The commercial appeal is straightforward: tests tend to gain traction faster when they can influence a difficult choice with treatment consequences.

What still needs to be proven

The main question is no longer whether Prosigna has a plausible role in care. It is whether that role turns into consistent ordering and durable revenue. That will depend on adoption across relevant patient groups, including higher-risk populations where the test may have the most impact. If that conversion happens, Veracyte gains a meaningful second growth layer on top of its existing portfolio.

TrueMRD taps the MRD theme through a narrower bladder-cancer beachhead

TrueMRD is the more exciting launch in market terms, but its first practical test is narrower: can Veracyte establish a valuable monitoring role in muscle-invasive bladder cancer before the story expands further. The test is a whole-genome, tumor-informed test for minimal residual disease detection in muscle-invasive bladder cancer. It looks for circulating tumor DNA after treatment, when conventional imaging may still show no evidence of disease.

Why the category matters

MRD testing is strategically interesting because it moves the diagnostic into the surveillance phase of care. In MIBC, that matters for patients who have completed definitive therapy and currently have no visible disease. If a test can detect molecular recurrence before scans do, it starts to matter not just scientifically, but clinically and commercially.

Why expectations should stay measured

The starting population is still specific. TrueMRD for MIBC is aimed at patients with cT2-cT4, N0-N2 disease who have already had definitive therapy and currently have no evidence of active disease. That makes it a focused beachhead, not a broad first-line offering. Bulls can argue that many successful diagnostic launches start that way. Skeptics will argue that the early addressable pool may keep near-term upside contained.

What will validate the thesis from here

The key issue now is operational proof. Veracyte has a core business delivering strong double-digit revenue growth while launching Prosigna as an LDT and TrueMRD for MIBC, and it previously generated more than $50 million of cash generated from operations in the fourth quarter. That gives the company room to invest and extend the launch phase.

What investors need to see next is not just a clean launch narrative. It is evidence that Prosigna and TrueMRD are becoming repeat testing streams, with adoption that holds up quarter after quarter. If that happens, Veracyte's growth story becomes more than the sum of its legacy business plus two new labels. If not, the thesis remains more promising than proven.